Skip to content
Enrolling by invitationPhase 2

Ketamine Effects on Learning In Eating Disorders

NCT06736769 · KETTLE · Amanda Downey, MD

Closed to entry
Status
Not accepting participants
Phase 2
Phase
20
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Mean Change From Baseline in Reversal Learning

    Measured over Day 2, Day 4

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

16 Years to 26 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Age 16-26 years old 2. Meets diagnosis of anorexia nervosa (AN) or atypical anorexia nervosa (atypical AN) per DSM-5 criteria on admission 3. Admitted to the medical hospital for malnutrition 4. No changes to psychiatric medications for month prior to trial enrollment 5. Agree to use a highly effective form of contraception for at least two weeks following ketamine administration 6. Have an outpatient primary care provider, medical provider, or behavioral health provider or psychiatrist who is actively managing or coordinating care Exclusion Criteria: 1. Lifetime history of any psychotic disorder 2. Moderate or severe substance use disorder 3. Pregnancy as indicated by a positive urine pregnancy test during screening, lactation, or the intention of becoming pregnant within 3 months of entry into this trial 4. Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) treatment within 30 days prior to enrollment 5. Intellectual or developmental disability 6. High risk for self-harm/suicide 7. Active laxative misuse or abuse 8. Biochemical refeeding syndrome or electrolyte abnormality 9. Cardiac abnormalities identified on admission 10. Taking medications that would be unsafe to administer with ketamine 11. Other medical condition or diagnosis, physical exam finding, laboratory abnormality, or health risk that would increase the risk of adverse events, at the discretion of the investigators

Where

1 study site

FacilityCityRegionCountry
University of California, San FranciscoSan FranciscoCaliforniaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06736769 on ClinicalTrials.gov →

Last updated in the registry 2026-06-12. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in